Jean-Yves Pierga Circulating Tumor Biomarkers Laboratory, SiRIC, Translational Research Department Institut Curie, PSL Research University Biography Publications Institution JoVE Articles Jean-Yves Pierga has not added a biography. If you are Jean-Yves Pierga and would like to personalize this page please email our Author Liaison for assistance. Publications Prognostic Impact of Residual HPV CtDNA Detection After Chemoradiotherapy for Anal Squamous Cell Carcinoma Clinical Cancer Research : an Official Journal of the American Association for Cancer Research. Jul, 2018 | Pubmed ID: 30054279 Clinical Potential of Circulating Tumour DNA in Patients Receiving Anticancer Immunotherapy Nature Reviews. Clinical Oncology. Oct, 2018 | Pubmed ID: 30050094 Cdk4/6 Inhibitors and Overall Survival: Power of First-line Trials in Metastatic Breast Cancer NPJ Breast Cancer. 2018 | Pubmed ID: 29951582 Fluctuation of the Left Ventricular Ejection Fraction in Patients with HER2-positive Early Breast Cancer Treated by 12 Months of Adjuvant Trastuzumab Breast (Edinburgh, Scotland). Oct, 2018 | Pubmed ID: 29913374 Circulating Tumor Cells in Breast Cancer Patients Treated by Neoadjuvant Chemotherapy: A Meta-analysis Journal of the National Cancer Institute. Jun, 2018 | Pubmed ID: 29659933 Lymphovascular Invasion After Neoadjuvant Chemotherapy is Strongly Associated with Poor Prognosis in Breast Carcinoma Breast Cancer Research and Treatment. Jun, 2018 | Pubmed ID: 29374852 Multiple Hotspot Mutations Scanning by Single Droplet Digital PCR Clinical Chemistry. Feb, 2018 | Pubmed ID: 29122835 RECIST Response and Variation of Circulating Tumour Cells in Phase 1 Trials: A Prospective Multicentric Study European Journal of Cancer (Oxford, England : 1990). 09, 2017 | Pubmed ID: 28743036 Genetic Heterogeneity in Therapy-Naïve Synchronous Primary Breast Cancers and Their Metastases Clinical Cancer Research : an Official Journal of the American Association for Cancer Research. Aug, 2017 | Pubmed ID: 28351929 Long-term Outcome of the REMAGUS 02 Trial, a Multicenter Randomised Phase II Trial in Locally Advanced Breast Cancer patients Treated with Neoadjuvant Chemotherapy with or Without Celecoxib or Trastuzumab According to HER2 Status European Journal of Cancer (Oxford, England : 1990). 04, 2017 | Pubmed ID: 28279941 Circulating Tumor Cells: Clinical Validity and Utility International Journal of Clinical Oncology. Jun, 2017 | Pubmed ID: 28238187 Patient-Specific Circulating Tumor DNA Detection During Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer Clinical Chemistry. Mar, 2017 | Pubmed ID: 28073896 FISH-in-CHIPS: A Microfluidic Platform for Molecular Typing of Cancer Cells Methods in Molecular Biology (Clifton, N.J.). 2017 | Pubmed ID: 28044298 A Whole-genome Sequence and Transcriptome Perspective on HER2-positive Breast Cancers Nature Communications. 07, 2016 | Pubmed ID: 27406316 Clinical Applications of Circulating Tumor DNA and Circulating Tumor Cells in Pancreatic Cancer Molecular Oncology. Mar, 2016 | Pubmed ID: 26856794 Circulating Tumor Cells in Breast Cancer Molecular Oncology. Mar, 2016 | Pubmed ID: 26809472 Pathological Complete Response and Prognosis After Neoadjuvant Chemotherapy for HER2-positive Breast Cancers Before and After Trastuzumab Era: Results from a Real-life Cohort British Journal of Cancer. Jan, 2016 | Pubmed ID: 26657653 Circulating Tumor DNA for Triple-negative Breast Cancer Diagnosis and Treatment Decisions Expert Review of Molecular Diagnostics. 2016 | Pubmed ID: 26568208 Clinical Utility of Circulating Tumor Cells in Metastatic Breast Cancer Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. May, 2015 | Pubmed ID: 25870091 High Purity Microfluidic Sorting and Analysis of Circulating Tumor Cells: Towards Routine Mutation Detection Lab on a Chip. May, 2015 | Pubmed ID: 25815443 Circulating Tumor Cell Thresholds and Survival Scores in Advanced Metastatic Breast Cancer: the Observational Step of the CirCe01 Phase III Trial Cancer Letters. May, 2015 | Pubmed ID: 25700777 Circulating Tumor DNA As a Non-invasive Substitute to Metastasis Biopsy for Tumor Genotyping and Personalized Medicine in a Prospective Trial Across All Tumor Types Molecular Oncology. Apr, 2015 | Pubmed ID: 25579085 Clinical Validity of Circulating Tumour Cells in Patients with Metastatic Breast Cancer: a Pooled Analysis of Individual Patient Data The Lancet. Oncology. Apr, 2014 | Pubmed ID: 24636208 Treatment of Malignant Gliomas in the Elderly Journal of Neuro-oncology. Jun, 1999 | Pubmed ID: 10533732 Single Droplet Digital Polymerase Chain Reaction for Comprehensive and Simultaneous Detection of Mutations in Hotspot Regions Charles Decraene1,2, Amanda Bortolini Silveira1, Marc Michel1, François-Clément Bidard1,3,4, Jean-Yves Pierga1,3,5, Marc-Henri Stern1,6, Charlotte Proudhon1 1Circulating Tumor Biomarkers Laboratory, SiRIC, Translational Research Department, Institut Curie, PSL Research University, 2CNRS UMR144, Institut Curie, PSL Research University, 3Department of Medical Oncology, Institut Curie, PSL Research University, 4University Versailles Saint-Quentin-en-Yvelines, 5University Paris Descartes, 6Inserm U830, Institut Curie, PSL Research University JoVE 58051 Genetik
Single Droplet Digital Polymerase Chain Reaction for Comprehensive and Simultaneous Detection of Mutations in Hotspot Regions Charles Decraene1,2, Amanda Bortolini Silveira1, Marc Michel1, François-Clément Bidard1,3,4, Jean-Yves Pierga1,3,5, Marc-Henri Stern1,6, Charlotte Proudhon1 1Circulating Tumor Biomarkers Laboratory, SiRIC, Translational Research Department, Institut Curie, PSL Research University, 2CNRS UMR144, Institut Curie, PSL Research University, 3Department of Medical Oncology, Institut Curie, PSL Research University, 4University Versailles Saint-Quentin-en-Yvelines, 5University Paris Descartes, 6Inserm U830, Institut Curie, PSL Research University JoVE 58051 Genetik